Key Takeaways
- Wegovy injection is the first obesity medication proven in a large outcomes trial (SELECT, n=17,604) to cut major cardiovascular events by 20%.
- Benefits stem from both sustained weight reduction and direct anti-inflammatory, vascular, and metabolic effects of semaglutide.
- Wegovy complements — and never replaces — prescribed heart medications such as statins, antihypertensives, or antiplatelet therapy.
Most people explore Wegovy (semaglutide) for weight management, yet landmark clinical outcomes research confirms weekly semaglutide injections also protect cardiovascular health in high-risk patients (1,2).
What the 17,604-patient SELECT trial discovered
Published in the New England Journal of Medicine, the SELECT trial enrolled more than 17,600 adults aged 45+ with overweight or obesity (BMI ≥27) and established cardiovascular disease (such as prior heart attack, stroke, or symptomatic peripheral arterial disease) without diabetes (1).
Participants receiving once-weekly semaglutide 2.4mg injections alongside standard heart care experienced a 20% lower risk of major adverse cardiovascular events (non-fatal heart attack, non-fatal stroke, or cardiovascular death) compared with placebo (1,2). (Note: this licensed cardiovascular indication currently applies specifically to Wegovy injections rather than the oral tablet.)
Why semaglutide protects the heart — and other emerging benefits
Losing even 5–15% of excess body weight reduces cardiac workload, triglycerides, and blood pressure (3). Beyond scale changes, research indicates semaglutide reduces systemic vascular inflammation, supports endothelial blood-vessel function, and improves metabolic signaling (4–6). Additional trial findings across STEP 1 and ESSENCE include:
- Prediabetes reversal: 84.1% of participants with prediabetes returned to normoglycemia at 68 weeks in STEP 1 (5).
- Systolic blood pressure reduction: Average -6.16 mmHg drop vs. -1.06 mmHg on placebo (5).
- Metabolic liver health (MASH): In the phase 3 ESSENCE trial, 62.9% of semaglutide patients achieved resolution of steatohepatitis without worsening fibrosis at 72 weeks vs. 34.3% on placebo (7).
Does Wegovy replace statins or blood pressure tablets?
Never. Every participant in SELECT continued their standard cardiovascular therapies (statins, antihypertensives, beta-blockers, or blood thinners). Semaglutide works alongside your cardiologist’s plan, never in place of it. Start a clinical evaluation at Amble to see if GLP-1 therapy fits your health history.
References
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221–2232.
- U.S. Food and Drug Administration. Wegovy (semaglutide) prescribing information — cardiovascular risk reduction indication.
- Centers for Disease Control and Prevention. Tips for losing weight & keeping it off.
- Yaribeygi H, et al. Anti-inflammatory benefits of semaglutide: State of the art. J Clin Transl Endocrinol. 2024;36:100340.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002.
- Eisa N, Barood O. Semaglutide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis. Endocr Pract. 2026;32(4):623–635.
- Sanyal AJ, Newsome PN, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE). N Engl J Med. 2025;392(21).
Your personalizedweight care plan
Clinician-prescribed GLP-1 & metabolic care, 100% online.